Sterne Kessler Director Jackie Bonilla, Ph.D., spoke at the 8th Annual Summit on Life Sciences IP Due Diligence, hosted by ACI. She participated in the session titled “The Politics and Policy of Conducting Life Sciences IP Due Diligence Under Trump 2.0” on Wednesday, December 3, 2025.

Session Overview

From changes at key federal agencies to international trade to new enforcement priorities and evolving legislation, these shifting policies in the new administration are affecting IP portfolios in the life sciences and the products they protect. As a result, these shifts may necessitate new or additional steps in your life sciences IP due diligence review.

  • Revamping your IP due diligence checklist to evaluate policy-related risk in furtherance of a deal
  • Examining how changes in workforce and policies at federal agencies may impact the value of your IP and your review
  • Analyzing manufacturing supply chains for potential red flags relative to imports
  • Ensuring the integrity of IP rights in international data acquisition
  • Tracking federal funding at the research and development levels in your diligence review
  • Understanding the impact of existing and pending federal legislation on life sciences IP and what this ultimately means for your diligence review
    • IRA
    • TRIPS agreement
    • H.R. 1
  • Considering the influences of federal agency and policy changes on internal corporate and personnel policies as a factor in your diligence review

Related Professionals

Related Services